Standard Chemical & Pharmaceutical Co Ltd (TW:1720) — Stock Price
Standard Chemical & Pharmaceutical Co Ltd (TW:1720) is currently trading at NT$56.70 TWD, down 0.53% today. Over the past 52 weeks, shares have ranged between NT$54.10 and NT$65.60. This page tracks Standard Chemical & Pharmaceutical Co Ltd's live share price on the TW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Standard Chemical & Pharmaceutical Co Lt (1720) total market value.
Standard Chemical & Pharmaceutical Co Ltd (1720) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Standard Chemical & Pharmaceutical Co Ltd's daily closing share price and trading volume on the TW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Standard Chemical & Pharmaceutical Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Standard Chemical & Pharmaceutical Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | NT$6.79 Billion | NT$6.24 Billion | NT$5.85 Billion | NT$4.60 Billion | NT$4.31 Billion |
| Cost of Revenue | NT$3.80 Billion | NT$3.51 Billion | NT$3.36 Billion | NT$2.54 Billion | NT$2.39 Billion |
| Gross Profit | NT$2.99 Billion | NT$2.73 Billion | NT$2.49 Billion | NT$2.07 Billion | NT$1.92 Billion |
| Research & Development | NT$288.09 Million | NT$266.27 Million | NT$251.88 Million | NT$241.79 Million | NT$227.21 Million |
| SG&A | NT$469.55 Million | NT$414.10 Million | NT$353.33 Million | NT$272.55 Million | NT$284.00 Million |
| Total Operating Expenses | NT$1.58 Billion | NT$1.47 Billion | NT$1.35 Billion | NT$1.19 Billion | NT$1.22 Billion |
| Operating Income | NT$1.40 Billion | NT$1.26 Billion | NT$1.44 Billion | NT$1.02 Billion | NT$774.06 Million |
| EBITDA | NT$2.06 Billion | NT$1.58 Billion | NT$1.66 Billion | NT$1.25 Billion | NT$1.01 Billion |
| EBIT | NT$1.65 Billion | NT$1.26 Billion | NT$1.36 Billion | NT$1.03 Billion | NT$777.45 Million |
| Interest Expense | NT$15.07 Million | NT$25.79 Million | NT$18.77 Million | NT$7.25 Million | NT$7.57 Million |
| Income Before Tax | NT$1.63 Billion | NT$1.44 Billion | NT$1.40 Billion | NT$1.01 Billion | NT$772.93 Million |
| Income Tax Expense | NT$333.05 Million | NT$279.94 Million | NT$246.31 Million | NT$176.95 Million | NT$147.37 Million |
| Net Income | NT$880.50 Million | NT$834.89 Million | NT$1.15 Billion | NT$706.73 Million | NT$524.17 Million |
Standard Chemical & Pharmaceutical Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Standard Chemical & Pharmaceutical Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | NT$11.18 Billion | NT$11.19 Billion | NT$10.97 Billion | NT$10.10 Billion | NT$7.05 Billion |
| Total Current Assets | NT$5.00 Billion | NT$5.42 Billion | NT$5.59 Billion | NT$5.78 Billion | NT$3.60 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$291.86 Million | NT$238.79 Million | NT$339.66 Million | NT$424.84 Million | NT$445.10 Million |
| Net Receivables | NT$1.34 Billion | NT$1.42 Billion | NT$1.48 Billion | NT$1.49 Billion | NT$942.84 Million |
| Inventory | NT$1.72 Billion | NT$1.61 Billion | NT$1.39 Billion | NT$1.22 Billion | NT$893.51 Million |
| Property, Plant & Equipment | — | — | NT$3.95 Billion | NT$2.96 Billion | NT$2.39 Billion |
| Goodwill | NT$173.91 Million | NT$173.91 Million | NT$173.91 Million | NT$162.24 Million | NT$70.27 Million |
| Total Liabilities | NT$2.20 Billion | NT$3.05 Billion | NT$3.53 Billion | NT$3.30 Billion | NT$2.14 Billion |
| Total Current Liabilities | NT$1.66 Billion | NT$2.37 Billion | NT$2.88 Billion | NT$2.72 Billion | NT$1.65 Billion |
| Long-term Debt | NT$163.95 Million | NT$222.97 Million | NT$182.00 Million | NT$50.00 Million | NT$0.00 |
| Net Debt | NT$-598.93 Million | NT$-708.86 Million | NT$-11.62 Million | NT$-594.48 Million | NT$-22.99 Million |
| Total Stockholder Equity | NT$5.91 Billion | NT$5.30 Billion | NT$4.75 Billion | NT$4.34 Billion | NT$3.97 Billion |
| Retained Earnings | NT$3.71 Billion | NT$2.28 Billion | NT$1.96 Billion | NT$1.75 Billion | NT$1.29 Billion |
Standard Chemical & Pharmaceutical Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Standard Chemical & Pharmaceutical Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$1.69 Billion | NT$1.34 Billion | NT$1.23 Billion | NT$827.03 Million | NT$922.58 Million |
| Capital Expenditures | NT$599.61 Million | NT$625.70 Million | NT$1.20 Billion | NT$217.92 Million | NT$352.49 Million |
| Free Cash Flow | NT$1.10 Billion | NT$710.83 Million | NT$30.29 Million | NT$609.12 Million | NT$570.09 Million |
| Investing Cash Flow | NT$-771.69 Million | NT$-485.50 Million | NT$-1.08 Billion | NT$819.12 Million | NT$-710.17 Million |
| Financing Cash Flow | NT$-1.44 Billion | NT$-1.08 Billion | NT$-465.44 Million | NT$-117.54 Million | NT$-643.98 Million |
| Dividends Paid | NT$482.48 Million | NT$446.74 Million | NT$446.74 Million | NT$321.65 Million | NT$268.04 Million |
| Stock-Based Compensation | — | — | — | — | NT$0.00 |
| Depreciation | NT$404.74 Million | NT$347.77 Million | NT$298.61 Million | NT$221.06 Million | NT$233.79 Million |
| Change in Cash | NT$-516.62 Million | NT$-222.64 Million | NT$-305.01 Million | NT$1.53 Billion | NT$-435.72 Million |
Standard Chemical & Pharmaceutical Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Standard Chemical & Pharmaceutical Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 25, 2026 | — | — | — |
| Nov 10, 2025 | 1.72 | 1.36 | +26.47% |
| Aug 06, 2025 | 1.10 | 1.36 | -19.12% |
| May 12, 2025 | 1.09 | 1.12 | -2.68% |
| Feb 25, 2025 | 1.09 | — | — |
| Nov 11, 2024 | 1.22 | 1.31 | -6.87% |
| Aug 07, 2024 | 1.21 | 1.14 | +6.14% |
| May 07, 2024 | 1.41 | 1.19 | +18.49% |